The Apothecary Shoppe Pharmacies

FDA Watch

• Zithromax (azithromycin): FDA Statement on risk of cardiovascular death A retrospective cohort study reports small increase in risk of cardiovascular deaths and risk of all cause deaths associated with 5 day course of antibiotic drug
• Hydromorphone Hydrochloride Injection 1 MG/ML, (C-II) 1 ML Fill In 2.5 ML Carpuject: Recall - May Contain More Than the Intended Fill Volume An overdose of Hydromorphone may result in life-threatening consequences, including respiratory depression (slowed breathing or suspension of breathing), low blood pressure, and reduced heart rate including circulatory collapse.
• Gilenya (fingolimod): Drug Safety Communication - Safety Review of a Reported Death After the First Dose UPDATED 05/14/2012. New recommendations for monitoring patients, and new contraindications, and dosing & administration information for use in certain patients.
• Revlimid (lenalidomide): Ongoing Safety Review - Increased Risk of Developing New Malignancies UPDATED 05/07/2012. Increased risk of developing acute myelogenous leukemia, myelodysplastic syndromes, and Hodgkin lymphoma in patients being treated with Revlimid.